Pompe Disease

A lysosomal storage disorder caused by acid alpha-glucosidase deficiency, driving glycogen accumulation in skeletal, cardiac, and respiratory muscle. The late-onset subtype carries a median diagnostic delay of 5–12 years.

About Pompe Disease

In numbers

Combined birth incidence approximately 1 in 18,711 live births (pooled analysis, 22 US states and 8 countries, 2024); late-onset Pompe incidence approximately 1 in 21,900.
Estimated 5,000–10,000 patients diagnosed in the USA; true prevalence including undiagnosed late-onset Pompe is substantially higher.
Newborn screening data reveals incidence 2–3 times higher than earlier clinical estimates, confirming a significant undiagnosed late-onset Pompe burden.

Special details

LOPD is pan-ethnic; founder mutations documented in Taiwanese, sub-Saharan African, and Chinese Han populations lead to significantly higher regional prevalence.
Infantile-onset Pompe (IOPD) presents in infancy with severe cardiomyopathy; LOPD typically manifests in the third to fifth decade with insidious proximal weakness.
Newborn screening now active across 22 US states and multiple countries identifies pre-symptomatic IOPD, transforming early treatment access.

Signs and symptoms of Pompe Disease

Median diagnostic delay for late-onset Pompe is approximately 7 years in USA and European cohorts. 97.1% of Chinese LOPD patients received at least one prior incorrect diagnosis before molecular confirmation.

Progressive proximal limb girdle weakness causing difficulty rising from chairs or climbing stairs

Commonly misattributed to limb-girdle muscular dystrophy.

Respiratory insufficiency from diaphragmatic involvement

With orthopnoea and nocturnal hypoventilation sometimes preceding limb weakness in up to 25% of LOPD patients.

Scoliosis and rigid spine

Scoliosis and rigid spine syndrome can mask the true degree of respiratory compromise during standard seated spirometry.

In infantile-onset Pompe: hypertrophic cardiomyopathy

Profound hypotonia, and feeding difficulty leading to cardiorespiratory failure before age two years.

Fatigue, exercise intolerance, and myalgia

Presenting under fibromyalgia, polymyositis, or chronic fatigue syndrome codes before the correct diagnosis is reached.

Key challenges from product development to launch

Strategy and Business

The wrong disease or indication selected for investment
Indications tackled in the wrong order due to shaky success estimates
R&D returns slipping below the cost of capital

Clinical Development

Trials delayed by low patient recruitment
High screen-failure rates that raise trial cost
Mixed cohorts that make the signals difficult to detect

HEOR, Access & Value

A value case that arrives too late or is underdeveloped
Eligible population under-counted, budget-impact case unsubstantiated
Approved by the regulator, delayed at HTA

Medical Affairs

Fragmented, differently-coded healthcare data
Diagnostic delay that is long and unequal
No shared evidence base across functions

Launch and Commercial

Launch planned without a view of the number of findable patients
Targeting too broad a population slows early uptake
RWE started too late to build the case

How Volv Global Helps

Strategy and Business

Pipeline mistakes compound from the earliest decisions: wrong indication, indications tackled in the wrong order, capital deployed where returns already trail the cost of capital.

inTrigue

Finds the true reachable population per candidate, so indication choices rest on evidence.

volv.global/finding-patients

inFlow

Adds probability-of-success and outcome evidence to help prioritise the pipeline.

volv.global/predict-patient-outcomes

Clinical Development

When patients cannot be found, recruitment stalls and the burn rate climbs. High screen failure rates add to the drain, and a mixed cohort makes the results harder to interpret.

inTrigue

Finds the undiagnosed and mis-coded patients conventional feasibility misses, widening the recruitable pool.

volv.global/finding-patients

inCare

Surfaces diagnosed-but-hidden, trial-eligible patients already in the data, so sites enrol faster.

volv.global/stratifying-patient-cohorts

inFlow

Predicts who will progress or respond, enriching the cohort so the signal is not diluted.

volv.global/predict-patient-outcomes

HEOR, Access & Value

Thin or late evidence lets payers restrict access or cut the price. A poorly sized population exposes the budget case, and HTA demands more than the regulator.

inFlow

Generates the real-world evidence and outcomes payers ask for, ahead of the submission deadline.

volv.global/predict-patient-outcomes

inTrigue

Finds the undiagnosed patients missing from the count, so the eligible population holds up under scrutiny.

volv.global/finding-patients

inCare

Surfaces the diagnosed-but-eligible patients who expand the eligible population count.

volv.global/stratifying-patient-cohorts

Medical Affairs

Fragmented data must be built market by market, slowing decisions. Time to correct diagnosis varies by who the patient is and where they receive care.

inTrigue

Works across fragmented, differently-coded data by design, so insight holds up country to country without a rebuild.

volv.global/finding-patients

inAdvance

Detects patients ahead of typical diagnosis, closing the gap in awareness and pathway that drives unequal delay.

volv.global/earlier-detection

Launch and Commercial

A launch without a view of findable patients is poorly resourced from day one. Targeting too broad a population slows early uptake, and late real-world evidence means the access dossier goes in rushed.